RxSight(US:RXST) Prnewswire·2025-07-29 14:59Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of misleading statements and failure to disclose significant operational challenges that have negatively impacted the company's financial performance [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $75,000 in RxSight between November 7, 2024, and July 8, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against RxSight, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [2][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against RxSight - The complaint alleges that RxSight and its executives violated federal securities laws by making false and misleading statements regarding the company's sales and product demand [4]. - Specific issues cited include "adoption challenges" leading to declines in sales and utilization, overstated demand for products, and an inability to meet previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second quarter 2025 financial results, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, due to significant declines in sales and lowered revenue guidance [5].